Abstract
Antibody-drug conjugates (ADCs) take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells. The recent approval of Adcetris™ and Kadcyla™ as well as emerging data from numerous ongoing clinical trials underscore the role of ADCs as a new therapeutic option for cancer patients. However, conventional conjugation methods generally result in a heterogeneous mixture of ADCs, which can result in significant therapeutic liabilities and can lead to complicated manufacturing processes. The increased understanding from the clinical investigation of current ADCs and site-specific bioconjugation technologies has enabled scientists to accelerate the discovery and development of the next generation ADCs with defined and homogeneous composition. The present manuscript reviews the recent advances and trends in the research and development of novel ADCs obtained by site-specific conjugation method.
Keywords: Antibody-drug conjugates, ADCs, conjugation site, DAR, homogeneous ADCs, site specific conjugation.
Current Cancer Drug Targets
Title:Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs)
Volume: 16 Issue: 6
Author(s): Wenlong Gao, Jingxin Zhang, Jun Xiang, Lei Zhang, Chengbin Wu, Pradeep K. Dhal and Bo Chen
Affiliation:
Keywords: Antibody-drug conjugates, ADCs, conjugation site, DAR, homogeneous ADCs, site specific conjugation.
Abstract: Antibody-drug conjugates (ADCs) take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells. The recent approval of Adcetris™ and Kadcyla™ as well as emerging data from numerous ongoing clinical trials underscore the role of ADCs as a new therapeutic option for cancer patients. However, conventional conjugation methods generally result in a heterogeneous mixture of ADCs, which can result in significant therapeutic liabilities and can lead to complicated manufacturing processes. The increased understanding from the clinical investigation of current ADCs and site-specific bioconjugation technologies has enabled scientists to accelerate the discovery and development of the next generation ADCs with defined and homogeneous composition. The present manuscript reviews the recent advances and trends in the research and development of novel ADCs obtained by site-specific conjugation method.
Export Options
About this article
Cite this article as:
Gao Wenlong, Zhang Jingxin, Xiang Jun, Zhang Lei, Wu Chengbin, K. Dhal Pradeep and Chen Bo, Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs), Current Cancer Drug Targets 2016; 16 (6) . https://dx.doi.org/10.2174/1568009616666160512144715
DOI https://dx.doi.org/10.2174/1568009616666160512144715 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member:
Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Human Insulin Genome Sequence Map, Biochemical Structure of Insulin for Recombinant DNA Insulin
Mini-Reviews in Medicinal Chemistry Telomerase as Drug and Drug Target for the Treatment of Thyroid Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Patent Selections:
Recent Patents on Drug Delivery & Formulation Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry The Structure and Pharmacological Functions of Coumarins and Their Derivatives
Current Medicinal Chemistry Fungal Secondary Metabolites: A Promising Source of Antineoplastic Drugs
Current Cancer Therapy Reviews A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia)
Letters in Drug Design & Discovery Affective Disorder and Hyperandrogenism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Non-Coding RNAs as Therapeutic Targets in Hepatocellular Cancer
Current Cancer Drug Targets Malignant Transformation of Mammary Epithelial Cells by Ectopic Overexpression of the Aryl Hydrocarbon Receptor
Current Cancer Drug Targets Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design Interaction and Reaction of the Antioxidant Mn<sup>III</sup> [Meso-Tetrakis(4-NMethyI Pyridinium) Porphyrin] with the Apoptosis Reporter Lipid Phosphatidylserine
Current Physical Chemistry Polyethyleneimine-Based Nanocarriers for Gene Delivery
Current Pharmaceutical Design Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics Kaempferol Improves TRAIL-Mediated Apoptosis in Leukemia MOLT-4 Cells by the Inhibition of Anti-apoptotic Proteins and Promotion of Death Receptors Expression
Anti-Cancer Agents in Medicinal Chemistry Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design